IDEX Corporation · IEX · FY2025 Q2 · Calendar Q3 2025
IDEX: Growth platforms advance, but guidance was lowered
IDEX's platform strategy and cost actions provide support, but the lowered outlook shows that policy volatility, order timing and semiconductor weakness currently outweigh the near-term growth opportunities.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about IEX FY2025 Q2
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, the outlook shifted from maintained guidance to lowered full-year guidance. Management also emphasized a broader acquisition and platform-integration agenda while continuing cost savings and tariff mitigation.
Guidance delta
Management lowered full-year revenue and EPS guidance, citing policy-driven demand volatility and slower order flow.
Key takeaways
- Q2 performance beat expectations, but management lowered full-year revenue and EPS guidance.
- Data-center thermal management, pharma, energy, water and fire-safety platforms remain identified growth areas.
- Cost optimization delivered savings in Q2 and management is continuing productivity initiatives.
- Recent acquisitions are intended to broaden capabilities and create cross-business synergies.
Management priorities
- Integrate Airtech and scale Micro-LAM within the platform strategy.
- Accelerate Mott growth and cross-business synergies.
- Continue cost containment, productivity work and platform R&D.
- Use pricing and operating actions to manage tariff-related pressure.
Follow IEX with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 10, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Oppenheimer | Outperform | Outperform | Maintain | Sep 9, 2026 |
| Mizuho | Outperform | Neutral | Upgrade | Aug 12, 2026 |
| DA Davidson | Neutral | Neutral | Maintain | Aug 6, 2026 |
| Argus Research | Buy | Buy | Maintain | Aug 6, 2026 |
| TD Cowen | Buy | Buy | Maintain | Jul 30, 2026 |
| Stifel | Buy | Buy | Maintain | Jul 30, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Jul 30, 2026 |
| Citigroup | Buy | Buy | Maintain | Jul 30, 2026 |
| BMO Capital | Market Perform | Market Perform | Maintain | Mar 27, 2026 |
| Baird | Outperform | Outperform | Maintain | Oct 31, 2024 |
| Wells Fargo | Overweight | Overweight | Maintain | Apr 28, 2023 |
| Bernstein | Market Perform | Market Perform | Maintain | Apr 28, 2023 |
| Morgan Stanley | Overweight | Overweight | Maintain | Jan 18, 2023 |
| Loop Capital | Hold | Hold | Maintain | Jul 19, 2022 |
| Cowen & Co. | Outperform | Market Perform | Upgrade | Mar 9, 2022 |
| Rosenblatt | Buy | Buy | Maintain | May 3, 2021 |
| Janney Montgomery Scott | Neutral | Buy | Downgrade | Apr 8, 2020 |
| Janney Capital | Neutral | Buy | Downgrade | Apr 8, 2020 |
| Stifel Nicolaus | Hold | Hold | Maintain | Jul 29, 2019 |
| Berenberg | Buy | Buy | Maintain | May 15, 2019 |
| UBS | Neutral | Neutral | Maintain | Jan 23, 2018 |
| KeyBanc | Equal Weight | Sector Weight | Maintain | May 23, 2016 |
| SunTrust Robinson Humphrey | Neutral | Neutral | Maintain | Nov 3, 2015 |
| Jefferies | Hold | Hold | Maintain | Jun 12, 2015 |
| Brean Capital | Buy | Hold | Upgrade | Jan 30, 2014 |
| Longbow Research | Neutral | Neutral | Maintain | Oct 1, 2013 |
| BB&T Capital | Hold | Hold | Maintain | Mar 15, 2013 |
| CL King | Neutral | Buy | Downgrade | Dec 12, 2012 |
| Barrington Research | Outperform | Outperform | Maintain | Jul 24, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $234.29. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Oppenheimer | Analyst unavailable | $270 | $225.66 | +15.2% | Sep 9, 2026 |
| Vertical Research | Jeffrey Sprague | $250 | $223.74 | +6.7% | Sep 8, 2026 |
| Mizuho Securities | Brett Linzey | $280 | $237.31 | +19.5% | Aug 11, 2026 |
| D.A. Davidson | Analyst unavailable | $240 | $234.88 | +2.4% | Aug 6, 2026 |
| Oppenheimer | Analyst unavailable | $265 | $236.82 | +13.1% | Jul 30, 2026 |
| Stifel Nicolaus | Nathan Jones | $268 | $229.52 | +14.4% | Jul 30, 2026 |
| Stifel Nicolaus | Nathan Jones | $257 | $224.94 | +9.7% | Jul 20, 2026 |
| RBC Capital | Analyst unavailable | $261 | $227.6 | +11.4% | Jul 16, 2026 |
| Oppenheimer | Analyst unavailable | $250 | $207.59 | +6.7% | Jun 2, 2026 |
| Seaport Global | Walt Liptak | $250 | $215.78 | +6.7% | May 5, 2026 |
| RBC Capital | Analyst unavailable | $252 | $217.93 | +7.6% | Apr 30, 2026 |
| Stifel Nicolaus | Analyst unavailable | $250 | $217.68 | +6.7% | Apr 30, 2026 |
| Oppenheimer | Analyst unavailable | $242 | $217.34 | +3.3% | Apr 30, 2026 |
| Robert W. Baird | Analyst unavailable | $257 | $217.34 | +9.7% | Apr 30, 2026 |
| Stifel Nicolaus | Analyst unavailable | $241 | $205.12 | +2.9% | Apr 14, 2026 |
| BMO Capital | Analyst unavailable | $214 | $189.73 | -8.7% | Mar 26, 2026 |
| Seaport Global | Analyst unavailable | $240 | $212.26 | +2.4% | Feb 9, 2026 |
| Argus Research | Analyst unavailable | $240 | $212.94 | +2.4% | Feb 6, 2026 |
| RBC Capital | Analyst unavailable | $244 | $211.02 | +4.1% | Feb 5, 2026 |
| Oppenheimer | Bryan Blair | $230 | $209.86 | -1.8% | Feb 5, 2026 |
| Robert W. Baird | Michael Halloran | $247 | $212.25 | +5.4% | Feb 5, 2026 |
| Stifel Nicolaus | Analyst unavailable | $220 | $196.43 | -6.1% | Jan 23, 2026 |
| RBC Capital | Analyst unavailable | $211 | $194.99 | -9.9% | Jan 15, 2026 |
| RBC Capital | Analyst unavailable | $195 | $175.97 | -16.8% | Oct 30, 2025 |
| Stifel Nicolaus | Analyst unavailable | $191 | $167.51 | -18.5% | Oct 20, 2025 |
| Oppenheimer | Analyst unavailable | $210 | $167.05 | -10.4% | Oct 7, 2025 |
| D.A. Davidson | Analyst unavailable | $180 | $158.25 | -23.2% | Aug 4, 2025 |
| Mizuho Securities | Brett Linzey | $185 | $190.85 | -21.0% | May 16, 2025 |
| Robert W. Baird | Michael Halloran | $215 | $181.45 | -8.2% | May 2, 2025 |
| Mizuho Securities | Brett Linzey | $175 | $166.4 | -25.3% | Apr 22, 2025 |
| RBC Capital | Deane Dray | $248 | $218.64 | +5.9% | Oct 31, 2024 |
| D.A. Davidson | Matt Summerville | $210 | $194.12 | -10.4% | Aug 5, 2024 |
| Oppenheimer | Bryan Blair | $238 | $192.75 | +1.6% | Aug 5, 2024 |
| Robert W. Baird | Michael Halloran | $256 | $224.64 | +9.3% | Apr 25, 2024 |
| Stifel Nicolaus | Nathan Jones | $265 | $225.83 | +13.1% | Feb 8, 2024 |
| Stifel Nicolaus | Nathan Jones | $188 | $186.26 | -19.8% | Jul 18, 2022 |
| RBC Capital | Deane Dray | $238 | $188.06 | +1.6% | May 9, 2022 |
| Citigroup | Analyst unavailable | $235 | $191.15 | +0.3% | Apr 28, 2022 |
| Mizuho Securities | Analyst unavailable | $205 | $191.42 | -12.5% | Apr 28, 2022 |
| Bernstein | Brendan Luecke | $230 | $224.3 | -1.8% | Jan 10, 2022 |
| D.A. Davidson | Matt Summerville | $220 | $222.43 | -6.1% | Oct 28, 2021 |
| Morgan Stanley | Connor Lynagh | $250 | $225.91 | +6.7% | Apr 29, 2021 |
Track every rating change on IEX the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationIDEX Corporation is an international enterprise specializing in engineered solutions across diverse sectors. The company operates through three primary business units: Fluid & Metering Technologies (FMT), Health & Science Technologies (HST), and Fire & Safety/Diversified Products (FSDP). The FMT division is responsible for the design, production, and distribution of a range of fluid-handling equipment, including positive displacement pumps, flow meters, and injectors, alongside offering flow monitoring and related services. Its applications span the food, chemical, general industrial, water management, agricultural, and energy industries. Under the HST umbrella, IDEX develops and supplies precision components and systems for health and scientific applications.…
Historical context
All IEX earningsIndustrials peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| DAL Delta Air Lines, Inc. | FY2026 Q3 · Calendar Q4 2026 | -2.8% | +0.0% | Delta reports strong Q3 demand while costs and capacity remain key watchpoints |
| CTAS Cintas Corporation | FY2027 Q1 · Calendar Q3 2026 | +3.0% | -3.4% | Cintas raises FY2027 guidance as Q1 growth broadens |
| PAYX Paychex, Inc. | FY2027 Q1 · Calendar Q3 2026 | +1.5% | -8.8% | Paychex maintains FY27 outlook as PEO and AI momentum strengthen |
| FPS Forgent Power Solutions, Inc. | FY2026 Q4 · Calendar Q3 2026 | +4.3% | +9.5% | Forgent Power Solutions pairs record results with an aggressive FY27 buildout |
| CPRT Copart, Inc. | FY2026 Q4 · Calendar Q3 2026 | -8.7% | -2.6% | Copart pairs international growth with ACV investment amid higher costs |
| SUNB Sunbelt Rentals Holdings Inc | FY2027 Q1 · Calendar Q3 2026 | +19.2% | +5.9% | Sunbelt raises FY27 outlook as specialty rental demand accelerates |
Latest beats and misses
Who reports nextBeat on EPS
Get the IEX recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:55.686058+00:00
- Polygon adjusted daily market bars · 2026-10-10T19:50:41.609033+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-10T19:50:41.606323+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-10. For educational purposes only; not investment advice.